BioCentury
ARTICLE | Clinical News

Diltiazem: Completed Phase III enrollment

January 9, 2012 8:00 AM UTC

Ventrus completed enrollment of 465 patients with anal fissures in a double-blind, placebo-controlled, European Phase III trial evaluating 2% and 4% diltiazem cream for 8 weeks. Ventrus has North Amer...